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Abstract
Background: Antiretrovirals have substantial promise for HIV-1 prevention, either as antiretroviral treatment (ART) for
HIV-1–infected persons to reduce infectiousness, or as pre-exposure prophylaxis (PrEP) for HIV-1–uninfected persons to
reduce the possibility of infection with HIV-1. HIV-1 serodiscordant couples in long-term partnerships (one member is
infected and the other is uninfected) are a priority for prevention interventions. Earlier ART and PrEP might both reduce HIV-
1 transmission in this group, but the merits and synergies of these different approaches have not been analyzed.
Methods and Findings: We constructed a mathematical model to examine the impact and cost-effectiveness of different
strategies, including earlier initiation of ART and/or PrEP, for HIV-1 prevention for serodiscordant couples. Although the cost
of PrEP is high, the cost per infection averted is significantly offset by future savings in lifelong treatment, especially among
couples with multiple partners, low condom use, and a high risk of transmission. In some situations, highly effective PrEP
could be cost-saving overall. To keep couples alive and without a new infection, providing PrEP to the uninfected partner
could be at least as cost-effective as initiating ART earlier in the infected partner, if the annual cost of PrEP is ,40% of the
annual cost of ART and PrEP is .70% effective.
Conclusions: Strategic use of PrEP and ART could substantially and cost-effectively reduce HIV-1 transmission in HIV-1
serodiscordant couples. New and forthcoming data on the efficacy of PrEP, the cost of delivery of ART and PrEP, and couples
behaviours and preferences will be critical for optimizing the use of antiretrovirals for HIV-1 prevention.
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s    Introduction
Thirty years after HIV-1 was first recognized, the epidemic
continues with 2.6 million people newly infected in the past year
[1]. Antiretroviral therapy (ART) can dramatically improve the
survival of HIV-1–infected persons and is the cornerstone of
strategies to prevent vertical HIV-1 transmission [2,3]. 5.2 million
people living with HIV-1 in low- and middle-income countries
have been provided with life-saving ART [1]; however, reduced
funding for AIDS programs as a result of the global economic
crisis threatens these acheivements, and a sustainable response to
the HIV-1 epidemic requires a large reduction in the numbers
becoming infected [1,4,5].
Many different forms of interventions are used to help reduce
the spread of HIV, and recently UNAIDS have proposed a
framework that prioritises condom promotion, interventions for
key populations, behaviour change programmes, male circumci-
sion, prevention of mother-to-child transmssion, and treatment for
people living with HIV as a basic set of program activities that
should form the core of responses to the epidemic [6]. Recently,
substantial scientific interest has developed in antiretroviral-based
strategies for prevention of sexual HIV-1 transmission [7,8]. In the
past year, four clinical trials have closed confirming that
antiretrovirals have the potential to be used as: (i) ART to reduce
the infectiousness of HIV-1–infected persons [9], and (ii) oral or
topical pre-exposure prophylaxis (PrEP) for uninfected persons to
reduce acquisition [10–12]. Although there is much scientific
enthusiasm about antiretroviral-based HIV-1 prevention, many
questions remain about how best to marshal these tools to achieve
the optimal impact [13,14]. Here we aim to synthesize these new
findings to understand how PrEP and ART could be used to
reduce HIV transmission in stable HIV serodiscordant couples.
ART reduces plasma and genital HIV-1 concentrations to
undetectable levels in most treated individuals [15,16], and
observational studies, and a recent large multicentre clinical trial,
have demonstrated large reductions in HIV-1 infectiousness
(.90% reduction in transmission risk) in persons receiving ART
[9,17–21]. WHO guidelines currently recommend ART initiation
at CD4 counts of ,350 cells/ml, although guidelines in many
African countries delay ART until CD4 counts decline to ,200
cells/ml because of constrained resources [22]. Apart from the
initial peak in viral load at seroconversion (during which
substantial proportions of transmission events could occur
[23,24]), the average per-contact risk of HIV-1 transmission is
highest from those with lower CD4 counts (i.e., below 200 cells/ml
[20,25]), and treatment could potentially reduce transmission from
those individuals. However, individuals can be infectious for many
years before the CD4 cell count declines to ,200 cells/mlo r
clinical disease necessitates ART, allowing for substantial potential
of HIV-1 transmission before treatment is started. Earlier ART
initiation, at higher CD4 counts, has therefore been proposed as
one HIV-1 prevention strategy [26,27].
A recent clinical trial of the pericoital use of topical 1%
tenofovir gel among HIV-1–uninfected women [10] demonstrated
a significant reduction in the risk of HIV-1 acquisition, by
approximately 40% overall and by .50% among those with high
adherence to the intervention. Two further clinical trials testing
the efficacy of daily oral tenofovir and oral emtricitabine-tenofovir
in serodiscordant couples and heterosexual women have recently
stopped, reporting a strong protective effect (.60%) of PrEP
[11,12]. These findings mirror those for daily oral PrEP in men
who have sex with men (the iPrEX study) [28]. One trial
(FemPrEP) testing the effect of oral daily emtricitabine tenofovir
PrEP in heterosexual women [29] and the part of a large trial (the
VOICE study) testing the effect of oral daily tenofovir in women
[30] have also been stopped after interim reviews found that it was
unlikely these studies would demonstrate benefit, and investiga-
tions in the likely causes for this are underway.
High enthusiasm for antiretroviral-based HIV-1 prevention has
been balanced by recognition of the need for strategies to
efficiently deliver these expensive new prevention options [8]. It
may be optimal and cost-effective in concentrated epidemics to
preferentially deliver these interventions to those at highest risk of
transmission, such as sex workers or individuals that inject drugs if
benefit is observed on on-going trials [31]. However, in the
generalized heterosexual epidemics in sub-Saharan Africa, most
transmission occurs outside of such easily identified risk groups [1].
One group that has been identified as a high priority for HIV-1
prevention is uninfected individuals in long-term sexual partner-
ships with HIV-1–infected individuals, i.e., stable HIV-1 serodis-
cordant couples [32–35]. The proportion of stable partnerships in
southern Africa that are serodiscordant has been estimated to be
between 10% and 20% [36], and in the community mobilization
work for the Partners in Prevention Study, 27% of couples tested
at three South African sites (Cape Town, Orange Farm, and
Soweto) were HIV-1 serodiscordant [37]. Condom use is typically
low in stable partnerships [38], particularly during periods when
couples desire pregnancy, during which the risk of HIV-1
acquisition and transmission is increased [39]. HIV-1 incidence
can be high in these partnerships and, importantly, not all of the
risk to the uninfected individual comes from their stable partner.
By comparing the genetic sequence of the virus in serodiscordant
couples where the HIV-1–uninfected partner became infected, it
has been estimated that the HIV-1–infected partner was not the
source of infection in approximately ,30% of couples [40]. In
these cases, PrEP—but not ART for the infected partner—could
offer protection against infections that might arise from additional
partners.
Given the constrained resources for HIV-1 treatment and
prevention in sub-Saharan Africa, many questions need to be
considered regarding the relative benefits and costs of PrEP and
earlier ART for HIV-1 prevention, specifically in potential target
groups such as HIV-1 serodiscordant couples, including: (i) Is there
any benefit of PrEP when ART is available and initiated promptly
upon meeting CD4 criteria for the HIV-1–infected partner and, if
there is, what patterns of PrEP use maximize this benefit?; (ii)
when might earlier ART initiation (at either CD4 cell count ,350
or ,500 cells/ml) in the HIV-1–infected partner be a more
effective use of resources than providing PrEP to the uninfected
partner?; and (iii) what is the best way to combine use of PrEP and
ART to maximize impact and efficiency? To address each of these
questions, we constructed an individual-based model describing
HIV-1 serodiscordant couples in South Africa in which the use of
PrEP and ART can be simulated and the effects on transmission
and life-years saved can be quantified.
Methods
Model Structure and Parameterisation
We constructed a microsimulation model of HIV-1 disease
progression, transmission of infection, and treatment in stable
HIV-1 serodiscordant heterosexual couples in South Africa. The
model included the composition of couples (by sex, age, and
current CD4 cell counts), ageing, disease progression, use of ART,
conception and pregnancies, variations in coital frequency within
stable partnerships and contact with other sexual partners. The
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Each result presented is the mean for sets of 20,000 simulated
couples. Key assumptions are summarized in Table 1 and a full
description and all parameter values are provided in Text S1. The
model was initially parameterised using data collected at three
South African sites (Cape Town, Orange Farm, and Soweto) that
participated in the Partners in Prevention HSV/HIV Transmis-
sion Study, a multinational prospective HIV-1 prevention clinical
trial among HIV-1 serodiscordant couples [41,42] in which the
HIV-1–infected partner had CD4 .250 cells/ml and was not
eligible for ART by national guidelines; we refer to this assumption
as the ‘‘partners in prevention’’ scenario. HIV-1 seroincidence was
relatively low (,1.8/100 person-years at risk [pyar]) in the
Partners in Prevention HSV/HIV Transmission Study cohort,
which was likely owing to selecting couples willing to participate in
an HIV-1 prevention clinical trial, frequent couples risk-reduction
counselling, and resultant high condom use. Therefore, we
constructed another set of assumptions, named ‘‘more typical
couples’’, in which 50% of the partnerships involved HIV-1–
infected men (to correspond to the gender distribution of HIV-1
serodiscordancy in population-based studies in Africa [34]),
condom use within the stable partnership was reduced to 75%
of that reported in the partners in prevention cohort, 50% more of
the HIV-1–uninfected partners in couples had external partners,
and the frequency of unprotected sex with external partners was
double that reported in the Partners in Prevention Study [41,42].
The assumptions made in the ‘‘more typical couples’’ scenario
were such that the overall incidence rate among these couples was
consistent with other empirical measurements of HIV-1 incidence
in serodiscordant couples (7.7/100 pyar in Zambia [43] and 9.2/
100 pyar in Uganda [21]) and reflected the balance of infections
from stable partners versus other partners implied by phylogenetic
analysis of viral sequences in couples in Rakai, Uganda [44].
Three other sets of assumptions about couples’ behaviour were
also made and the results are shown in the supplementary
materials (Text S1).
The parameter for the ‘‘effectiveness’’ of PrEP, which combines
assumptions about the ‘‘intrinsic efficacy’’ of PrEP and levels of
adherence to the regimen (Text S1), is analogous to the estimates
of effect size that have been generated in PrEP clinical trials. In the
initial analyses we assumed effectiveness values as high as 80% (the
upper limit of the 95% confidence interval for the effect of oral
emtricitabine-tenofovir in serodiscordant was 85% [11] and the
estimate of effect for men and women receiving tenofovir in
another study was 78% [12]) and as low as 30% (the lower limit of
the 95% confidence interval for the effect of tenofovir in
serodiscordant couples was 34% [11]). As well as the statistical
imprecision in the effect size found in the trials, this range also
reflects that the effectiveness of PrEP in ‘‘real-world’’ roll-out may
not reproduce that found in clinical trials.
The cost of one person-year of PrEP was assumed to range
between US$150 and US$250 on average (this includes lab testing,
personnel, and drug costs), and the approximate costs of each
additional person-year of ART was set at US$450–US$800 [45–
47]. This assumption gives a range for the PrEP costs per year as a
fraction of the ART costs per year of 18% to 56%. All cost
calculations incorporate an annual discount rate of 3%.
Analysis
The model was analyzed by running a ‘‘baseline’’ scenario in
which the only intervention was the initiation of ART for the
infected partner, with initiation occurring when their CD4 cell
count fell below 200 cells/ml (which until recently was the South
African guideline for asymptomatic or nonpregnant HIV-infected
individuals [48] and other settings) or 350 cells/ml (assuming
adoption of the revised WHO ART initiation guidelines [22]).
Relative to this baseline scenario, the impact of particular PrEP
and/or ART interventions on three outcomes was quantified: (i)
HIV-1 infections averted, which represents the reduction in the
number of couples in which the initially HIV-1–uninfected partner
is infected before their 50th birthday; (ii) being ‘‘alive and HIV-1
free at age 50,’’ which represents the increase in couples whose
HIV-1–uninfected partner is uninfected at his/her 50th birthday
and both members of the couple survive to their 50th birthdays;
(iii) quality-adjusted life-years (QALYs) saved, which represents the
total extra QALYs accrued by the couple because of the
intervention. The person-years lived by each partner in the couple
are weighted according to the utility associated with each health
state (uninfected or infected and according to CD4 cell count
category or treatment-status) [49].
These outcomes were chosen to capture the long-term impact
on couples, so that the cumulative risk of transmission/death and
total costs can be fully reflected. The latter two outcomes record
the beneficial effects of these interventions on survival and quality
of life, as well as HIV-1 transmission rates.
Three analyses were conducted to address the questions
outlined above. In the first analysis, the impact of four different
PrEP implementation strategies was examined (Table 2). In a
second analysis, one strategy for PrEP use was compared with an
alternative intervention of initiating ART for the HIV-1–infected
partner earlier than is the current practice in many African
countries (i.e., ART initiation at CD4 counts #350 cells/mlo r
#500 cells/ml). In a final analysis, an optimal combination of PrEP
and ART was analyzed by comparing the cost and efficiency of a
range of candidate combination strategies.
Results
The Additional Impact of Different PrEP Interventions in
the Context of Routine ART Initiation
The modelled impact of the four PrEP implementation
strategies in the ‘‘partners in prevention’’ couples and ‘‘more
typical couples’’ is shown in Figure 1 (bars assume a PrEP
effectiveness ranging from 30% to 80%). For both types of couples,
the greatest number of infections is averted (14%–59% and 15%–
52%, respectively) when PrEP is used at all times, irrespective of
ART use by the HIV-1–infected partner (Figure 1A and 1D:
strategy I). PrEP has a greater proportionate effect in the ‘‘partners
in prevention’’ couples because the overall risk of transmission is
lower at baseline. The number of infections averted was somewhat
less (14%–43% and 11%–36%) if PrEP was discontinued when the
HIV-1–infected partner initiated ART (strategy III) or 1 y
afterwards (17%–49% and 10%–43%; strategy II) because of
continued HIV-1 risk from outside partners and from ART
discontinuation in the HIV-1–infected partners. Because the HIV-
1–infected partner’s infectiousness decreases gradually after ART
is initiated, the estimated number of infections averted was only
marginally higher if PrEP is used during the first year of ART
(strategy II) rather than discontinuing PrEP in the HIV-1–
uninfected partner immediately upon ART initiation by their
HIV-1–infected partner (strategy III). Using PrEP only during
periods of trying to conceive a pregnancy and during pregnancy
(strategy IV) averts only a small proportion of infections overall
(2%–10% and 1%–2%), because the time spent protected by PrEP
is short relative to the many years the couples spend together. This
model does assume, however, that there is some continued risk of
transmission of HIV in the couples when they are not trying to
conceive, and although this has been observed in cohort studies
HIV Prevention in Serodiscordant Couples
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to use PrEP in this way.
The four PrEP strategies differed in the amount of PrEP used
(Figure 1B and 1E, blue bars). Using PrEP throughout the
duration of the partnership (strategy I) resulted in an average of
,15 y (‘‘partners in prevention’’) or ,12 y (‘‘more typical
couples’’) of PrEP use per couple, whilst only using PrEP up to
the initiation of treatment (strategy III) uses ,7–8 y of PrEP per
couple, and only using PrEP during conception and pregnancy
(strategy IV) uses less than 1 y of PrEP per couple. The PrEP
Table 1. Key assumptions made in the model.
Parameter Values Source
Infectiousness of untreated individuals (relative
to those with CD4 cell count $500 cells/ml)
CD4 350–500: 1.00 Cohort of stable serodiscordant couples [20]
CD4 200–350: 1.59
CD4 0–200: 4.99
Mean time spent in CD4 cell count category (y)
a Infection to CD4 of 500: 2.4 Pooled analysis of African observational cohort
studies [66]
CD4 350–500: 2.4
CD4 200–350: 4.6
CD4 0–200: 2.6
Relative infectiousness of those on ART (relative to
those untreated with CD4 cell count ,350 cells/ml)
0.08 Cohorts of stable serodiscordant couples [17,20]
Mortality rates on ART (per year) Multinational observational cohort studies [67–69]
First year:
ART initiation at CD4 500+: 1.3%
ART initiation at CD4 350–500: 2.5%
ART initiation at CD4 200–350: 5%
ART initiation at CD4 0–200: 10%
Subsequent years:
ART initiation at CD4 500+: 1.3%
ART initiation at CD4 350–500: 1.3%
ART initiation at CD4 200–350: 2.5%
ART initiation at CD4 0–200: 5%
Drop-out from ART (per year) First year: 10%; subsequent years: 5% Observational data from programs in Zambia [70]
PrEP effectiveness 30%–80% (in Figure 1) Consistent with the ranges of effectiveness reported
in a large trial of PrEP in serodiscordant couples [11]
Full cost per year of ART US$450–US$800 (midpoint: US$625) [45–47]
Full cost per year of PrEP US$150 and US$250 (midpoint: US$200) [53]
Relative annual cost of PrEP compared to ART 18%–56% (midpoint: 32%) Calculated from values given above
aMean time elapsed between entering category (CD4 cell count reaching value of upper bound) and exiting category (CD4 cell count drops below value of lower
bound).
doi:10.1371/journal.pmed.1001123.t001
Table 2. PrEP implementation strategies used in the model.
Strategy Description
Baseline No PrEP
a
I Always use PrEP after diagnosis of HIV-1 serodiscordancy in couples
II Use PrEP up to the initiation of ART for the stable HIV-1–infected partner, and during the first year of the partner’s ART use
b, then stop PrEP
III Use PrEP up to the initiation of the stable HIV-1–infected partner on ART, then stop PrEP
IV Use PrEP only during periods of trying to conceive a pregnancy
c and during pregnancy
In strategies I–III, PrEP is initiated following HIV-1 testing of couples, and, in all strategies, PrEP is stopped immediately if the HIV-1–infected partner dies or the initially
HIV-1–uninfected partner becomes HIV-1 infected.
aIn this and all other scenarios, it is assumed that ART is initiated promptly when the infected partner’s CD4 cell count reaches 200 cells/ml.
bAn initial period of continued PrEP is allowed until viral load becomes suppressed after ART initiation in the HIV-1–infected partner. PrEP could reasonably be
discontinued after an interval of less than 1 y, or be based on viral load monitoring of the infected partner instead.
cIn the model, pregnancies can be preceded by a period of ‘‘trying to conceive a pregnancy’’ during which the frequency of unprotected sex increases (see Text S1).
doi:10.1371/journal.pmed.1001123.t002
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by the couple, because when an infection is averted the protected
individual will not later require ART (Figure 1B and 1E, yellow
bars). The average amount of ART saved (yellow bars) correlates
with the average number of infections averted, with up to 2 y
(‘‘partners in prevention’’) or 4 y (‘‘more typical couples’’) of ART
potentially saved if PrEP were to be used throughout the
partnership (strategy I). In comparison, strategies II and III used
substantially less PrEP while saving less total ART.
Costs per infection averted were calculated taking into account
the lifetime costs of PrEP and ART for the initially uninfected
individual who seroconverts. In the ‘‘partners in prevention’’
couples (Figure 1C), under strategy I (when PrEP is always used)
each infection averted costs between US$6,000 and US$66,000
(depending on the effectiveness and the cost per year of PrEP). We
note that these costs are lower than the ‘‘up-front’’ only cost of
PrEP (US$11,000–US$69,000 per infection averted because the
total costs also reflect the eventual ART savings that accrue for
each infection averted. The most cost-effective strategies were
strategies II and III (using PrEP prior to ART initiation by the
HIV-1–infected partner or up until 1 y after ART initiation),
which gave a minimum expected cost of US$3,000 per infection
averted, for the model with the highest assumed effectiveness
(80%), lowest assumed PrEP cost, and highest assumed ART cost.
This result can also been seen when comparing the incremental
cost and impact of PrEP in averting infections (Figure S1) between
the PrEP strategies: the incremental cost-effectiveness of using
PrEP prior to ART initiation (scenario II/III) compared to not
using PrEP (baseline scenario) is high, whereas the marginal
benefits of additionally using PrEP whilst their partner is on ART
(scenario I) is small relative to the extra cost. Because scenarios II
and III give similar costs and benefits (especially when compared
with the other scenarios simulated: see Figure S1 and the overlap
of confidence intervals), and because any decision to cease PrEP
use at the time of a partner’s ART initiation may also be informed
by monitoring clinical symptoms, CD4 cell count, and viral load
(rather than simply time elapsed since initiation), no further
analyses are conducted to differentiate these two scenarios.
In the ‘‘more typical couples’’, costs per infection averted were
much lower (Figure 1F), because increased sex in the couple and
more external partners results in more infections in the absence of
PrEP, and so a greater number of infections can be averted. With
these assumptions, the net cost per infection averted under strategy
I ranged between ,US$0 (‘‘break-even’’) and US$26,000, and,
under strategy III, between US$–2,200 (net cost-saving) and
US$21,000. The estimated cost per infection averted when using
PrEP only during conception or pregnancy (strategy IV) was
highly variable in simulations (due to the relatively rare occurrence
of pregnancy in uninfected partners in this situation prior to their
partner starting ART), but overall the model indicated that this
strategy could be a cost-effective way to use PrEP (cost per
infection range was US$–2,000 to US$12,000 for ‘‘partners in
prevention’’ and US$–6,000 to US$8000 for ‘‘more typical
couples’’).
Figure 1. The impact of different PrEP interventions on HIV infections in the couple. (A, D) The proportion of infections averted by age 50
(relative to a baseline strategy with no PrEP intervention) for four PrEP strategies (see Table 2). (B, E) The expected mean years on PrEP (blue boxes)
and years on ART averted (yellow boxes) for each of the four PrEP interventions (after discounting). (C, F) The expected cost per infection averted for
each of the four PrEP interventions: the pink boxes reflect the lower PrEP cost estimates (and the higher ART cost estimates) and the blue boxes
reflect the higher PrEP cost estimates (and the lower of ART cost estimates). In (A–F), the boxes shows a ‘‘feasible’’ range of results, which corresponds
to a functional effectiveness of PrEP ranging between 50% and 80%. The assumptions used about the couple’s behaviour are: (A–C) ‘‘partners in
prevention’’ assumptions and (D–F) the ‘‘more typical couples’’ assumptions (see main text for details). Figure S2 shows the analysis repeated for
alternative types of couples. (Summary of strategies from Table 2: I, always PrEP; II, PrEP prior to ART with 1-y overlap; III, PrEP prior to ART (no
overlap); IV, PrEP during conception/pregnancy.)
doi:10.1371/journal.pmed.1001123.g001
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QALY saved are: for 30% effective PrEP, US$2,500–US$4,900
per QALY in ‘‘partners in prevention’’ couples or US$700–
US$1,900 per QALY in ‘‘more typical couples’’ (depending on
cost of PrEP); and for 80% effective PrEP, US$260–US$1,600 per
QALY in ‘‘partners in prevention’’ couples or US$–200 (cost-
saving) to US$500 per QALY in ‘‘more typical couples’’. This
result places PrEP among the more expensive public health
interventions [50,51], although it does likely meet the thresholds
for costs per life-year saved suggested by WHO for the region [52].
The analyses were repeated in three other sets of couples with
different types of behaviours (Figure S2). Compared to the
‘‘partners in prevention’’ assumptions, the cost per infection
averted was lowest if it was assumed that condoms were used less
frequently by the couple, because more transmissions occur prior
to the HIV-1–infected partner’s initiation of ART. For the ‘‘more
typical couples’’ with more external partners, there was a greater
relative advantage in using PrEP regardless of the known HIV-1–
infected partner’s ART use, because PrEP will reduce the risk of
HIV-1 acquisition from all partners, whereas ART for the stable
HIV-1–infected partner only reduces the infectiousness and
likelihood of transmission from their known HIV-1–infected
partner. If a higher proportion of men were assumed to be
initially infected, the results were similar to those in the models
with ‘‘partners in prevention’’ behaviour assumptions.
Comparison of PrEP and Earlier ART Initiation
We performed a comparison between an intervention that
provides PrEP to the HIV-1–uninfected partner until the HIV-1–
infected partner initiates ART at CD4,350 cells/ml (strategy III)
and an intervention providing earlier ART initiation to the
infected partner at a CD4 cell count of 500 cells/ml but no PrEP.
Both interventions increase cost and reduce infections. The
comparison metric was the number of couples ‘‘alive and HIV-1
free at age 50.’’ Figure 2 shows the required properties for PrEP
(relative cost and effectiveness) to be at least as cost-effective as
earlier ART initiation under these assumptions. With the assumed
behaviours observed among the ‘‘partners in prevention’’ couples,
PrEP would be at least as cost-effective as earlier ART if its
effectiveness was more than ,75% and the annual cost was less
than 40% that of ART (Figure 2, dark shaded area). At the upper
estimate of the relative annual cost of PrEP (56% of ART costs
[53]), PrEP effectiveness would need to be more than 90% to be at
least as cost-effective as earlier ART initiation at #500 cells/mli n
these couples.
A much broader range of PrEP effectiveness and cost values
render PrEP at least as cost-effective as earlier ART if the
behaviours characterizing the ‘‘more typical couples’’ are assumed
(Figure 2, lighter shaded area). In this case, with the highest current
cost estimates, PrEP would be at least as cost-effective as earlier
ART initiation at 350 cells/ml if it has effectiveness greater than
,40%. This result is because, in these couples, there is a high risk of
infection before ART is started and a lower proportion of
transmissions are from the stable HIV-1–infected partner (thus,
reducing the infectiousness of the HIV-1–infected partner using
ARTinthestableHIV-1–infected partneronlypartiallyreducesthe
risk to the HIV-1–uninfected partner). The analyses are repeated
for different assumptions about couples’ behaviour in Figure S2.
We repeated these analyses in the context of earlier ART
initiation, comparing PrEP use prior to ART initiation at CD4 cell
Figure 2. Comparison of PrEP versus earlier ART initiation for keeping couples ‘‘alive and HIV free at 50.’’ The relative cost of PrEP to
ART (vertical axis) and the effectiveness of PrEP (horizontal axis) are varied and the shaded region indicates the conditions where a PrEP intervention
(PrEP used up to the moment that their infected partner starts treatment (at CD4,350 cells/ml)) is at least as cost-effective as earlier initiation of ART
(at CD4,500 cells/ml) at allowing couples to be ‘‘alive and HIV-1 free at 50.’’ The dark shaded region corresponds to the ‘‘partners in prevention’’
assumptions about couples’ behaviour and the lighter shaded region corresponds to ‘‘more typical couples’’ behaviour assumptions. Alternative
analyses are presented where different assumptions about ART initiation and couples’ behaviour are made (Figure S3) and where the comparison is
based on savings of QALYs (Figure S4).
doi:10.1371/journal.pmed.1001123.g002
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ml. The pattern is similar to the previous analysis and in ‘‘more
typical couples’’, PrEP with effectiveness of 50% could have an
annual cost as much as 70% that of ART and be as cost-effective
as earlier ART initiation for the HIV-1–infected partners. At the
upper-bound of the estimate for relative PrEP-to-ART costs, PrEP
would be as cost-effective as initiating ART in the HIV-1–infected
partner at CD4,500 cells/ml if PrEP was more than 40%
effective.
Both analyses were repeated using the QALY outcome (Figure
S3). Here, the requirements for PrEP to be more cost-effective
than earlier ART (at either #350 or #500 cells/ml) become more
stringent (although the differences with respect to the alternative
types of couples, described above, remain.) For example, for PrEP
and ART at 350 cells/ml to be more cost-effective than ART at
500 cells/ml in ‘‘more typical couples’’, PrEP should have an
effectiveness greater than ,50% if the per-year cost of PrEP was
half that of ART, compared to ,40% using the ‘‘alive and HIV-1
free’’ outcome. This result is because a new infection is a much less
severe outcome than a premature death when considering utilities
in the QALY calculation, whereas infection and premature death
are given equal weight in the ‘‘alive and HIV-1 free at 50’’
outcome.
An additional analysis quantified the influence of the assumed
mortality and drop-out rates on infections averted for couples for
whom ART is initiated at CD4 cell counts ,500 cells/ml instead of
CD4,200 cells/ml (Figure S5). With 50% higher drop-out rates
and 25% higher mortality rates on ART than previously assumed,
a small marginal benefit (in terms of infections averted and life-
years for the couple) is maintained with earlier initiation of ART,
whereas with correspondingly reduced drop-out and mortality
rates, the benefit of earlier ART initiation is greater. Further
research into the actual drop-out and mortality rates for those
initiated on treatment at high CD4 cell counts will therefore be
useful in refining this analysis of the trade-offs between earlier
ART and the potential use of PrEP.
Optimal Combinations of PrEP and ART
To determine the best overall strategies for the use of PrEP and
ART among HIV serodiscordant couples, the impact (on couples
being ‘‘alive and HIV free at 50’’) and cost (net lifetime costs of
treatment and PrEP to the couple) of the full range of possible
different strategies were calculated. The strategies were: ART
initiated by the HIV-1–infected partner at 200 cells/ml with no
PrEP or with PrEP used by the uninfected partner until their
partner initiates ART (with varying degrees of PrEP effectiveness:
30%, 60%, or 80%); with ART initiated at 350 cells/ml with no
PrEP or with PrEP used by the uninfected partner until ART
initiation by their partner (with the same values for PrEP
effectiveness); and ART initiated at CD4 count of 500 cells/ml.
The impact of all strategies were compared against no treatment.
This information is summarized in ‘‘impact versus cost’’ plots
(Figure S6).
For both types of couple modelled, in the absence of the option
to use PrEP, earlier treatment initiation (up to treatment at
CD4,500) could be the most efficient way, among these options,
to spend resources in order to keep couples alive and HIV free (but
not necessarily an optimal use of resources across a whole HIV
program portfolio), although this would be associated with an
increase in costs (additional cost compared to treatment at
CD4,200: US$2,700 in ‘‘partners in prevention’’ couples and
US$3,700 in ‘‘more typical couples’’). However, if using PrEP
were possible and the effectiveness was greater than 30%–40%
(assuming the midpoint to high estimate for PrEP cost) then the
overall most effective strategy for HIV prevention in higher risk
(‘‘more typical’’) couples be to offer PrEP to the uninfected
partners prior to their partners’ treatment initiation.
Discussion
The analysis provides three main results. First, PrEP used prior
to ART initiation can prevent infections in HIV-1 serodiscordant
couples and, although the initial costs are high, they are
substantially offset by reduced future ART costs among HIV-1–
uninfected partners who remain uninfected. In some circumstanc-
es (e.g., with effectiveness of 80% and used in couples that remain
at high-risk), PrEP could be cost-saving overall. Second, PrEP in
serodiscordant couples could be as cost-effective as earlier
initiation of ART (compared to existing practice) if PrEP has a
sufficiently high effectiveness (.70%) and low cost of delivery
(,40% annual cost of ART). If used in couples that remain at high
risk, PrEP could be as cost-effective as earlier ART even if PrEP
had effectiveness of ,40%. Third, in lower risk couples, earlier
ART at CD4,500 may be the most cost-effective strategy, but, in
couples that remain at high risk, PrEP and ART could be used
together (PrEP in the uninfected individual prior to ART initiation
for their HIV-1–infected partner) to deliver maximal benefit and
best cost-effectiveness. We hope this might inform the choices that
will be available for HIV prevention in couples. We note, however,
that it is important that many other considerations besides cost-
effectiveness should inform decision-making for HIV treatment
initiation and provision of PrEP in couples, including equitable
access and the preferences of the couples themselves.
The principal determinants of the eventual use of PrEP among
stable serodiscordant couples will be PrEP effectiveness, relative
costs of PrEP and ART delivery, and couples’ sexual behaviour.
Using the model, we have defined a ‘‘target product profile,’’ the
cost and effectiveness level for PrEP at which its use in a couple
would to be at least as cost-effective as starting ART earlier in
couples with different patterns of behaviour. The model shows
that, if couples risk behaviour is reduced through risk reduction
counselling, and becomes more like the behaviours reported by the
‘‘partners in prevention’’ clinical trial couples, then earlier
initiation of ART is probably a more cost-effective way to manage
infection and prevent HIV-1 infection (i.e., keeping couples ‘‘alive
and HIV free’’), unless PrEP in ‘‘real world’’ settings is at least as
effective as indicated in recent trials among couples [11].
However, the model also shows that, in couples with risks similar
to those recorded in observational studies (‘‘more typical’’
behaviour assumptions [21,43]), with a PrEP effectiveness similar
to that observed in recent trials [11], and at a cost of delivery
consistent with optimistic forecasts [53], PrEP use among the
uninfected partner could be as cost-effective as earlier treatment,
and even a cost-saving intervention in its own right. This outcome
highlights how the behavioural profile of couples influences the
potential utility of PrEP and illustrates the importance of
maximizing efficiency by prioritizing interventions for highest risk
couples. It also shows the need for further research into the
behaviours of those in long-term serodiscordant couples, their
responses to the counselling, and their preferences for these
different forms of intervention, in order to develop responsive and
appropriate programs.
We note that although the feasibility of delivering ART is
proven, the feasibility of PrEP is unknown and currently being
investigated, so the information available about each option is not
equal. Nonetheless, this analysis does support that PrEP could
become one reasonable option that couples in this situation can be
offered. And greater choices in HIV prevention should be
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better protection overall.
These calculations should also inform decision making about
investment in new technologies—for instance, by setting a limit on
the cost for potential future longer-lasting PrEP formulations that
may be more effective. All these considerations are, of course,
influenced by the estimated cost of ART, which, through
renegotiated drug supply contracts and task-shifting in clinics,
might be expected to fall considerably in the coming years [54],
which would tend to make earlier ART more cost-effective.
We have explored these trade-offs using a detailed mathematical
model that is parameterized and calibrated with data from stable
serodiscordant heterosexual couples in South Africa, which
included information on the sources of infection for those
acquiring HIV-1 (i.e., whether infected by their stable partner or
another partner). However, these couples may have lower risks of
infection than HIV-1 serodiscordant couples in the general
population due to study eligibility criteria and their participation
in intensive HIV-1 prevention counselling during a clinical trial.
Nonetheless, PrEP delivery programs would require initial HIV
testing, and ideally will promote and provide couples HIV
counselling and testing, so knowledge of serostatus and condom
use will likely increase as has been reported among HIV
serodiscordant couples in other studies [55,56]. Sensitivity analyses
were used to explore how differences in sexual behaviour affected
the results. The data available from the Partners in Prevention trial
[41,42] cannot fully specify the long-term behaviour of couples in
the model because couples were only followed for a 2-y period,
whereas the model tracks individuals over their adult lifetimes.
The use of the extended time-horizon of the simulation enabled
the analysis to reflect the cumulative risk of transmission/death
and total costs, whereas a short-term approach would not indicate
whether infections in couples are averted or just delayed and
would not capture the full cost implications of different strategies
(e.g., because life-years saved and ART costs may follow many
years after initial PrEP costs). The choice of outcome measure
depends upon the relative value placed on preventing death and
preventing HIV infection. The QALY approach emphasizes
reduced deaths whereas the ‘‘alive and HIV free’’ metric gives
more weight to HIV infection, which would often be survived with
treatment. Giving more weight to averted infections also helps to
implicitly reflect reduced risk of onward HIV transmission.
If further data become available about the added clinical
benefits to patients of ART initiation at higher CD4 cell counts
rather than indicated in current national and international
guidelines, then these should be used to update the model and
revise this analysis. We also note that in the analysis the wider
benefits of the intervention (or the cost of nonintervention), such as
increased labour availability and economic growth, are not
included in the calculations. Issues regarding the trade-offs
between PrEP and ART for immediate clinical need, including
the attendant ethical considerations, are important in the wider
debate about resource allocation in HIV programs, but were not
relevant here because we only investigated use of PrEP in couples
after universal access to ART (at current national and interna-
tional guidelines) has been achieved. Many countries aim to
achieve this by 2015 [57], but we recognize that realistically this
may not be achieved until many years later [1].
Many simplifying assumptions were made in the model,
including not representing any change in risk behaviours during
ART or PrEP use (i.e., potential ‘‘risk compensation’’ from feeling
less at risk due to PrEP or ART use), the long-term interaction
between PrEP and ART effectiveness through selection of resistant
strains of virus [58,59], or potential effects of sexually transmitted
infections on the efficacy of ART or PrEP [60]. The model, and
the chosen outcome measures, also do not capture the external
sexual partner network so that, for instance, it does not account for
the possibility that an averted infection terminates a chain of
further infections [61], including averted infections among
children. This factor may be expected to influence the estimated
impact of ART and PrEP similarly (although further work is
required to examine this) because, while ART reduces transmis-
sion to the infected individual’s other partners, PrEP reduces the
chance of infection and the subsequent risk of onward transmission
to their partners, including during the initial highly infectious
phase [25]. The model also does not reflect that the HIV-1
prevalence and infectiousness among external partners will be
influenced by patterns of PrEP and ART use in the wider
population [62,63]. The impact of ART on the incidence of other
diseases, particularly tuberculosis, was not explicitly captured and
this could lead to an underestimation of the benefit of ART,
although the CD4-level–specific mortality rates in untreated
individuals and utility-weights in the QALY analysis should
implicitly reflect the deterioration in health that is associated with
advanced HIV-1 infection [64]. Interpretation of the results is
further complicated by key uncertainties in the estimates of the
cost of PrEP, which is inevitable given that PrEP delivery
programs have not yet been implemented. However, the analyses
presented here reflect these uncertainties and it is reassuring that
our assumptions for the annual cost of PrEP (and the ratio of PrEP
to ART costs) are similar to those independently derived by
Pretorius et al. [63]. Although these results suggest that the use of
PrEP in HIV-1 serodiscordant couples could be cost-effective and
have a significant impact on HIV incidence for that group, there
are still significant logistical challenges that are not captured in the
model. The identification and retention of discordant couples in
services varies from setting to setting, and has been shown to be
particularly difficult in South Africa. In such settings the feasibility
and cost of targeting discordant couples (and, in particular, couples
in which the woman might be pregnant/trying to conceive) could
make an intervention utilizing PrEP much more expensive. Lastly,
although we hope that this model will assist in policy-making
decisions, we recognize that other factors beyond effectiveness and
cost will also influence the introduction of PrEP for certain groups.
This analyses focuses on heterosexual HIV-1 serodiscordant
couples in sub-Saharan Africa but similar questions could be asked
for other groups such as men who have sex with men (MSM) in
Africa and elsewhere. Different behavioural, biological, and
program parameter values would be required for analyses in
these different high risk groups reflecting for example the much
higher risk of transmission per unprotected sex act [65] in MSM
and the higher cost of treatment for MSM in developed countries.
However, the same general principles would apply: the lower the
cost and the higher the effectiveness of PrEP, the more likely it is
that PrEP will be a cost-effective way to support serodiscordant
couples.
In summary, PrEP might become a valuable addition to
combination approaches for HIV-1 prevention among stable
serodiscordant couples in sub-Saharan Africa, in conjunction with
ART. If PrEP is used by individuals that remain at high risk of
infection prior to a partner’s ART initiation, the additional cost
per infection averted might be smaller than previously anticipated
or the intervention could even be cost-saving, and the use of PrEP
could be as cost-effective as earlier ART initiation. However, this
outcome completely relies on the delivery cost of PrEP meeting
current forecasts, and the ‘‘real-world’’ effectiveness of PrEP in
couples being comparable to that found in the clinical trial [11]: if
adherence to PrEP outside of trials is lower, or if PrEP is more
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effective. It is vital to understand these trade-offs as soon as
possible so that programmatic decision making and implementa-
tion can quickly proceed.
Supporting Information
Figure S1 Incremental costs and impact of different
PrEP implementation strategies for (A) ‘‘partners in
prevention’’ couples and (B) ‘‘more typical couples’’. In
(A) and (B), the extra lifetime (discounted) cost of ART and PrEP
(horizontal axis) and the numbers of couples in which an HIV
infection is averted (by the age of 50) (vertical axis) are compared
when PrEP is: (i) not used (baseline simulation, black star); (ii)
always, purple polygon); (iii) up to ART initiation of partner and
one year more, red polygon; (iv) up to ART initiation of partner,
blue polygon (Table 2). The boundaries of the polygon are given
by the ranges of PrEP efficacies and costs given in Table 1. The
dot indicates the midpoint of the polygon and the black line
connects the scenarios with the highest impacts (infections averted)
at different levels of cost.
(PDF)
Figure S2 The impact of different PrEP interventions in
each of the three alternative types of couples (less
condom use, more external partners, and more infected
men) relative to the characteristics of the partners in
prevention cohort. (A, C, E) The proportion of infections
averted (relative to a baseline scenario with no PrEP intervention)
for each of the four PrEP interventions (see Table 2). (B,D,F) The
expected cost per infected averted for each of the four PrEP
interventions: the pink and blue boxes reflect the lower and higher
of the PrEP cost estimates and the higher and lower of the ART
cost estimates, respectively. In (A–F), the boxes show a feasible
range of results, which corresponds to a functional efficacy of PrEP
ranging between 50% and 80%.
(PDF)
Figure S3 Comparison of PrEP versus earlier ART
initiation. This is the same analysis as shown in Figure 2 in
the main text but with the frontiers shown for each of the five sets
of couples assumptions [see Text S1]. In (A) and (B), the relative
cost of PrEP to ART and the functional effectiveness of PrEP are
varied. (A) The area to the right of the lines demarcates a region
where PrEP use prior to partners’ treatment at CD4 cell count
below 200 would lead to more couples being ‘‘alive and HIV Free
at 50’’ than an ART intervention of the same cost whereby the
infected partner is initiated on treatment at CD4 cell count below
350. (B) The area to the right of the lines demarcates a region
where PrEP use prior to partners’ treatment at CD4 cell count
below 350 would lead to more couples being ‘‘alive and HIV free
at 50’’ than an ART intervention of the same cost whereby the
infected partner is initiated on treatment at CD4 cell count below
500. The different lines show the frontier for the following
assumptions about couples behaviour: ‘‘partners in prevention,’’
solid black line (as shown in Figure 2); ‘‘less condom use,’’ dashed
blue line; ‘‘more extra partners,’’ dashed green line; ‘‘more men
infected,’’ solid grey line; and ‘‘more typical couples’’, dashed pink
line (as shown in Figure 2). Cost is calculated as the total lifetime
discounted cost of person-years on PrEP and ART of both
partners in initially HIV-1 serodiscordant couples.
(PDF)
Figure S4 Comparison of PrEP versus earlier ART
initiation. This is the same analysis as shown in Figure S2 but
with outcome defined as QALYs [see Text S1]. In (A) and (B), the
relative cost of PrEP to ART and the functional effectiveness of
PrEP are varied. (A) The area to the right of the lines demarks a
region where PrEP use prior to partners’ treatment at CD4 cell
count below 200 would lead to a greater gain in QALYs than an
ART intervention of the same cost whereby the infected partner
is initiated on treatment at CD4 cell count below 350. (B) The
area to the right of the lines demarcates a region where PrEP use
prior to partners’ treatment at CD4 cell count below 350 would
lead to a greater gain in QALYs than an ART intervention of the
same cost whereby the infected partner is initiated on treatment
at CD4 cell count below 500. The different lines show the frontier
for the following assumptions about couples’ behaviour: ‘‘partners
in prevention,’’ solid black line (as shown in Figure 2); ‘‘less
condom use,’’ dashed blue line; ‘‘more extra partners,’’ dashed
green line; ‘‘more men infected,’’ solid grey line; and ‘‘more
typical couples’’, dashed pink line (as shown in Figure 2). Cost is
calculated as the total lifetime discounted cost of person-years on
PrEP and ART of both partners in initially HIV-1 serodiscordant
couples.
(PDF)
Figure S5 The effect of drop-out and mortality assump-
tions on the impact of ART. Comparisons of the infections
averted in couples (A) and the QALYs accrued by the couple with
treatment initiated at CD4,200 (blue bars) or CD4,500 (red
bars) making different sets of assumptions about mortality on ART
and drop-out from ART. The assumptions about mortality and
drop-out from ART are as follows: ‘‘default assumptions’’ uses the
parameter values given in Table 1; ‘‘lower drop-out and
mortality’’ uses mortality-rates that are 25% lower and drop-out
rates that are 50% lower; ‘‘higher drop-out and mortality’’ used
mortality-rates that are 25% higher and drop-out rates that are
50% higher.’’
(PDF)
Figure S6 Impact versus costs for combination strate-
gies of ART and PrEP. (A) ‘‘Partners in prevention couples’’
and (B) ‘‘more typical couples.’’ The strategies depicted are: no
intervention, purple star; ART initiated by the HIV-1–infected
partner at 200 cells/ml with no PrEP, solid blue triangle or with
PrEP used by the uninfected partner until their partner initiates
ART (with varying degrees of PrEP effectiveness: open blue circle,
30%; open blue diamond, 60%; or open blue pentagram, 80%);
with ART initiated at 350 cells/ml with no PrEP, solid red triangle,
or with PrEP used by the uninfected partner until ART initiation
by their partner (with the same values for PrEP effectiveness and
respective shapes in red); and ART initiated at CD4 count of 500
cells/ml, solid black triangle.
(PDF)
Text S1 Description of the model structure and all
parameter values used in the model with detailed
justifications and explanations.
(PDF)
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Background. Every year, about 2.5 million people become
infected with HIV, the virus that causes AIDS. HIV is usually
transmitted through unprotected sex with an HIV-infected
partner. It destroys immune system cells (including CD4 cells,
a type of lymphocyte), leaving infected individuals
susceptible to other infections. There is no cure for AIDS,
although HIV can be held in check with antiretroviral therapy
(ART), and there is no vaccine that protects against HIV
infection. So, to halt the AIDS epidemic, other ways of
preventing the spread of HIV are needed. Antiretroviral
drugs could potentially be used in two ways to reduce HIV
transmission. First, ART could be given to HIV-infected
people before they need it for their own health to reduce
their infectiousness; the World Health Organization currently
recommends that HIV-positive people initiate ART when
their CD4 count drops below 350 cells/ml blood but in many
African countries ART is only initiated when CD4 counts fall
below 200 cells/ml. Second, ART could be given to HIV-
uninfected people to reduce acquisition of the virus. This
approach—preexposure prophylaxis (PrEP)—has provided
protection against HIV transmission in some but not all
clinical trials.
Why Was This Study Done? Couples in long-term
relationships where one partner is HIV-positive and the
other is HIV-negative (HIV serodiscordant couples) are a
priority group for prevention interventions. In sub-Saharan
Africa, where most new HIV infections occur, 10%–20% of
stable partnerships are serodiscordant and condom use is
often low, not least because such couples may want
children. Earlier ART or PrEP might reduce HIV transmission
in this group but the merits of different approaches have not
been analyzed. In this study, the researchers use a
mathematical model to examine the long-term impact and
cost-effectiveness of different PrEP and ART strategies for HIV
prevention in serodiscordant couples.
What Did the Researchers Do and Find? The researchers
constructed a model to simulate HIV infection and disease
progression among hypothetical HIV serodiscordant stable
heterosexual couples. The model incorporated data from
South Africa on couple characteristics, disease progression,
ART use, pregnancies, frequency of sex, and contact with
other sexual partners, as well as estimates of the
effectiveness of PrEP from clinical trials. The researchers
used the model to compare the impact on HIV transmission,
survival and quality of life, and the cost-effectiveness of no
PrEP with four PrEP strategies—always use PrEP after
diagnosis of HIV serodiscordancy, use PrEP up to and for a
year after ART initiation by the HIV-infected partner (at a CD4
count of #200 cells/mlo r#350 cells/ml), use PrEP only up to
ART initiation by the infected partner, and use PrEP only
while trying for a baby and during pregnancy. The model
predicts, for example, that the cost per infection averted of
PrEP used before ART initiation will be offset by future
savings in lifelong treatment, particularly among couples
with multiple partners, low condom use, and a high risk of
transmission. To keep couples alive without the HIV-
uninfected partner becoming infected, it could be more
cost-effective to provide PrEP to the uninfected partner than
to initiate ART earlier in the infected partner, provided the
annual cost of PrEP is less than 40% of the annual cost of ART
and PrEP is more than 70% effective. Finally, if PREP is 30%–
60% effective, the most cost-effective strategy for couples
could be to use PrEP in the uninfected partner prior to ART
initiation in the infected partner at a CD4 count #350 cells/
ml.
What Do These Findings Mean? These findings suggest
that the strategic use of PrEP and ART could cost-effectively
reduce HIV transmission in HIV serodiscordant stable
heterosexual couples in sub-Saharan Africa. The accuracy of
these findings depends on the assumptions included in the
mathematical model and on the data fed into it. In particular,
the interpretation of these results is complicated by
uncertainties in the likely cost of PrEP and the ‘‘real-world’’
effectiveness of PrEP. Nevertheless, these findings suggest
that PrEP may become a valuable addition in some settings
to existing approaches for HIV prevention such as condom
promotion and male circumcision programs. Moreover,
additional simulations with this mathematical model using
more accurate information on the costs and effectiveness of
PrEP could assist in future policy making decisions.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001123.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
summaries of recent research findings on HIV care and
treatment, and a section on PrEP
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on all aspects of HIV prevention, and on HIV/AIDS in
Africa (in English and Spanish)
N AVAC Global Advocacy for HIV Prevention provides up-to-
date information on all aspects of HIV prevention,
including PrEP
N The US Centers for Disease Control and Prevention also has
information on PrEP
N WHO provides information about antiretroviral therapy
N Patient stories about living with HIV/AIDS are available
through Avert and through the charity website Healthtalk-
online
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